CG Oncology Files S-1/A Amendment
Ticker: CGON · Form: S-1/A · Filed: Dec 11, 2024 · CIK: 1991792
| Field | Detail |
|---|---|
| Company | Cg Oncology, Inc. (CGON) |
| Form Type | S-1/A |
| Filed Date | Dec 11, 2024 |
| Risk Level | medium |
| Pages | 11 |
| Reading Time | 13 min |
| Key Dollar Amounts | $1.0674, $120 million, $1.2872, $105 million, $14.57 |
| Sentiment | neutral |
Sentiment: neutral
Topics: ipo, registration, amendment
TL;DR
CG Oncology just amended its S-1 filing. IPO incoming?
AI Summary
CG Oncology, Inc. filed an S-1/A amendment on December 11, 2024, to its registration statement. The company, incorporated in Delaware, is in the biological products sector and is headquartered in Irvine, CA. This filing is an amendment to their initial registration, likely related to an upcoming public offering.
Why It Matters
This S-1/A filing indicates CG Oncology is moving forward with its public offering process, which could provide significant capital for its biopharmaceutical operations.
Risk Assessment
Risk Level: medium — As a biopharmaceutical company undergoing an IPO, there are inherent risks associated with market volatility, regulatory approvals, and clinical trial success.
Key Numbers
- 2836 — SIC Code (Biological Products (No Diagnostic Substances))
- 37-1611499 — IRS Number (Employer Identification Number)
Key Players & Entities
- CG Oncology, Inc. (company) — Registrant
- December 11, 2024 (date) — Filing Date
- 333-283725 (registration_number) — SEC File Number
- Arthur Kuan (person) — Chief Executive Officer
- Irvine, CA (location) — Principal Executive Offices
- Cooley LLP (company) — Legal Counsel
FAQ
What is the purpose of this S-1/A filing?
This is Amendment No. 1 to the Form S-1 Registration Statement, indicating updates or revisions to the initial filing for a public offering.
When was this amendment filed with the SEC?
The amendment was filed on December 11, 2024.
What is CG Oncology, Inc.'s primary business sector?
CG Oncology, Inc. is in the Biological Products sector, specifically SIC code 2836.
Where are CG Oncology, Inc.'s principal executive offices located?
The principal executive offices are located at 400 Spectrum Center Drive, Suite 2040, Irvine, CA 92618.
Who is listed as the agent for service for CG Oncology, Inc.?
The agent for service is listed as Arthur Kuan, Chief Executive Officer, with the same address as the principal executive offices.
Filing Stats: 3,244 words · 13 min read · ~11 pages · Grade level 13.4 · Accepted 2024-12-11 16:09:22
Key Financial Figures
- $1.0674 — preferred stock at a purchase price of $1.0674 per share, for aggregate consideration
- $120 million — ggregate consideration of approximately $120 million. 2. In July 2023, we issued to inves
- $1.2872 — preferred stock at a purchase price of $1.2872 per share, for aggregate consideration
- $105 million — ggregate consideration of approximately $105 million. No underwriters were involved in the
- $14.57 — hted-average exercise II-2 price of $14.57 per share, to certain of our employees,
Filing Documents
- d872865ds1a.htm (S-1/A) — 92KB
- d872865dex11.htm (EX-1.1) — 227KB
- d872865dex51.htm (EX-5.1) — 8KB
- g872865g1204220714664.jpg (GRAPHIC) — 2KB
- 0001193125-24-275552.txt ( ) — 331KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Irvine, State of California, on this 11th day of December, 2024. CG ONCOLOGY, INC. By: /s/ Arthur Kuan Arthur Kuan Chairman and Chief Executive Officer Pursuant to the requirements of the Securities Act of 1933, this registration Signature Title Date /s/ Arthur Kuan Arthur Kuan Chairman and Chief Executive Officer (principal executive officer) December 11, 2024 /s/ Corleen Roche Corleen Roche Chief Financial Officer (principal financial and accounting officer) December 11, 2024 * Susan Graf Director December 11, 2024 * Brian Liu, M.D. Director December 11, 2024 * James J. Mulé, IPh.D. Director December 11, 2024 * Leonard Post, Ph.D. Director December 11, 2024 * Simone Song Director December 11, 2024 * Victor Tong, Jr. Director December 11, 2024 By: /s/ Arthur Kuan Arthur Kuan Attorney-in-Fact II-7